Browse Primary Care/Hospitalist Articles by Topic

Secukinumab Injection (Cosentyx™)

A recombinant, fully humanized monoclonal antibody to interleukin-17 has been approved for the treatment of moderate-to-severe plaque psoriasis. Secukinumab is marketed by Novartis as Cosentyx.

B-type Natriuretic Peptides (BNP) Values Improve CVD Risk Prediction

Elevated BNP values in a large cohort of women with numerous CV events modestly improved measures of CVD risk prediction.

Does a Link Exist Between OSA and CAD?

Obstructive sleep apnea is associated with coronary artery calcification in non-obese individuals, but the effect is largely attenuated by body mass index.

Statins After an MI: Does it Happen?

Following hospital discharge for a heart attack, the majority of Medicare patients do not get recommended high-intensity statin therapy.

Clinical Briefs

Ambulatory BP Monitoring, A New Oral Treatment for Hyperkalemia: Patiromer, Obesity Leads to Overdiagnosis of Airflow Obstruction

Strengthen the Feet to Treat Plantar Fasciitis

SYNOPSIS: A strength training exercise improved self-reported 3-month outcomes in treating plantar fasciitis compared with inserts and stretching.

Effects of Coenzyme Q10 in Chronic Heart Failure Patients

SYNOPSIS: Treatment with coenzyme Q10 in addition to standard therapy for patients with moderate to severe HF is safe, well tolerated, and associated with a reduction in symptoms and major adverse cardiovascular events.

Is BMI Good Enough to Measure Visceral Adiposity?

SYNOPSIS: A large international study found frequent discordance between body mass index (BMI) and waist circumference (WC), driven by the substantial variability in visceral adiposity. Within each BMI category, patients with the highest WC were more likely to have higher cardiometabolic risk.

HPV screening: Option to cytology-based options

Primary human papillomavirus (HPV) screening can be considered as an alternative to current U.S. cytology-based cervical cancer screening methods, according to new interim guidance from the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology.¹

Data reaffirm the effectiveness of LNG, copper intrauterine devices

Findings from a recent analysis of data from a large, multi-country study of women using levonorgestrel or copper intrauterine devices (IUDs) indicate that while both forms of contraception have high levels of efficacy, the levonorgestrel device daily releasing 20 mcg (Mirena LNG IUD, Bayer Healthcare Pharmaceuticals, Wayne, NJ) was associated with a significantly lower risk of pregnancy, including ectopic pregnancy, than copper IUDs.¹